EX-99.1 2 dp10820_ex9901.htm
 
EXHIBIT 99.01
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
   
Press Release
  
 
 
Notification of major interests in shares

Basingstoke, UK and Philadelphia, US – July 30, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire Limited

2. Reason for the notification
State
Yes/No
An acquisition or disposal of voting rights
  
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
Yes
An event changing the breakdown of voting rights
  
Other (please specify):  New Exemption DTR 5.1.3 (4) & DTR 5.1.5 (1)
  

3. Full name of person(s) subject to the notification obligation:
ExcellerateHRO Share Plan Services (Guernsey) Limited
4. Full name of shareholder(s) (if different from 3.):
  
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
13 May 2008
6. Date on which issuer notified:
30 July 2008
7. Threshold(s) that is/are crossed or reached:
3%
8. Notified details:
  

A: Voting rights attached to shares

Class/type of shares
 if possible using the ISIN CODE
Situation previous to
the Triggering
transaction
Resulting situation after the triggering
transaction
 
Number
of
Shares
Number
of
Voting
Rights
Number
of
shares
Number of voting
rights
% of voting
rights
     
Direct
Direct
Indirect
Direct
Indirect
JE00B2QKY057
ADRs
Below 3%
Below 3%
  
8,524,960
2,791,605
8,524,960
8,374,815
  
1.52%
1.50%
  


Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument
Expiration
date
Exercise/Conversion
Period/ Date
Number of voting
rights that may be
acquired if  the instrument
is exercised/converted
% of voting
rights
         


Total (A+B)
  
Number of voting rights
% of voting rights
16,899,775
3.02%


9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
 
 
 
ExcellerateHRO act as trustees of the Shire Employee Benefit Trust and the holdings when the threshold was exceeded was as follows: 
 
Shares Held By
 
 
Registered in the name of
No of consolidated Shares Held
Statestreet Nominees Ltd
ExcellerateHRO SPS (Gsy) Ltd
1,917,710
Equiniti Registrars
ExcellerateHRO SPS (Gsy) Ltd
39,250
Morgan Stanley
ExcellerateHRO SPS (Gsy) Ltd
6,568,000
Morgan Stanley
ExcellerateHRO SPS (Gsy) Ltd
3,910,500
JP Morgan
ExcellerateHRO SPS (Gsy) Ltd
4,464,315
     
Total Shares held by ExcellerateHRO Guernsey Ltd as at 13th May 2008 16.899,775
 
Proxy Voting:

10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will cease to hold:
N/A
12. Date on which proxy holder will cease to hold voting rights:
N/A

13. Additional information:
  
14. Contact name:
Emma Holland
15. Contact telephone number:
01481 726088

Contact at Shire Limited: Tony Guthrie, Deputy Company Secretary, 01256 894746
 

For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.